Arylepoxamides
Arylepoxamides are a new class of analgesics that have potent efficacy with limited side effects.
Pipeline
Precision Neuropsychiatry
Use of fMRI and advanced analytics to develop and discover drugs for neuropsychiatric diseases.
Mitragynine Derivative
Derived from the Kratom plant, this class of drug has potential for the treatment of opioid use disorders.
Arylepoxamides
Pain relief without the side effects
Arylepoxamides are novel compounds which binds to a newly discovered receptor, AEAr. The AEAr is widely distributed thoughout the neuro-axis. In preclinical studies, arylepoxamides demonstrate potent analgesia and a clean safety profile lacking respiratory depression, physical dependence and reward behavior.
SBS-1000 - i.v. / s.c. formulation
Preclinical IND-enabling tox ongoing
Phase 1 clinical anticipated in 2021
SBS-1226 - oral formulation
Discovery / preclinical development
SBS-972 - i.v. / s.c. formulation
Discovery / preclinical development
Mitragynine Derivatives
Attacking addiction and overdose head on
Mitragynine derives from the kratom plant. The Pasternak lab has characterized its unique pharmacologic profile. It has attributes which make it a suitable candidate for opioid use disorder.
SBS-1027
Discovery / Preclinical Development
Precision Neuropsychiatry
Bringing personalized medicine to the brain
Sparian is collaborating with a spin out of the Brigham and Women's Hospital/Harvard Medical School which is pioneering the use of functional MRI (fMRI) technology and advanced analytics to better understand the neurobiology of disease and the response to treatment. We are looking to use this technology to enhance the precision and success of neuropsychiatric drug development.